Isodiol International Inc (ISOLF)

[MarketProphet]

Positive update on $ISOLF


ORIGINAL: Isodiol International Inc. to Present, Exhibit at 25th Annual American Academy of Anti-aging Medicine World Congress



2017-12-07 11:00 ET - News Release


LAS VEGAS, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, announced today that Dr. Ronald Aung-Din, Medical, Science and Development Advisor at Isodiol, will present at the 25th Annual American Academy of Anti-Aging Medicine (A4M) World Congress being held at the Venetian/Palazzo Resort in Las Vegas, December 14-16.

Dr. Aung-Din, a board-certified neurologist with more than 35 years of experience in general neurology and neuro-psychiatry, will take the stage to discuss how Direct Effects Technology™ has refashioned the application of CBD for those suffering from conditions such as Parkinson’s disease, peripheral neuropathy and cluster headaches. Direct Effects is a patented non-systemic delivery system utilized in Isodiol’s IsoDerm Direct Effects Cream. The topical is applied to the back of the neck at the hairline, where it is picked up by the free nerve endings located in the dermis of the skin for a highly effective delivery of the compound.

“We have long been working with neurologists and physicians in Brazil to bring relief to patients using this technology and look forward to having our newly appointed advisor, Dr. Aung-Din, share the science behind Direct Effects with A4M attendees,” said Marcos Agramont, CEO of Isodiol. “Direct Effects has made IsoDerm more effective for those suffering from neurological, psychiatric, and physical pain. We plan to develop further products utilizing the Direct Effects delivery method.”

The speaking engagement follows Isodiol’s announcement that the company has acquired the global rights for the patented Direct Effects Technology. The licensing rights apply to IsoDerm, as well as five other propriety pharmaceutical compounds to be delivered by the Direct Effects system. The official press release can be viewed here.

IsoDerm Direct Effects Cream, along with Isodiol’s diverse product line which includes non-cannabis CBD tablets, transdermal patches, and CBD-infused beverages, will be exhibited during the event at BOOTH 4085.

For more information on Isodiol, please visit www.isodiol.com

About Isodiol International Inc.

Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.

Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.

Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.

Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter:@isodiol

ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director

INVESTOR RELATIONS:
[e-mail]
www.isodiol.com

MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
[e-mail]